Lapatinib substantially reduced tumor growth in mice with mammary tumors refractory to trastuzumab. Moreover, phosphorylation and activation of p95HER2 was downregulated after lapatinib treatment.

“We observed that the majority of our trastuzumab resistant cell lines remain sensitive to lapatinib, providing further evidence that these two agents have independent mechanisms of resistance.

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Trastuzumab appears to improve outcomes in patients with BM secondary to controlling extra-CNS disease, which remains the main cause of cancer-related mortality. The single-agent lapatinib has a ...

A randomised, multicentre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2+/ErbB2+ primary breast cancer. A randomised, ...

A total of 104 patients were enrolled, of whom 53 received DV and 50 received Lapatinib plus Capecitabine. All patients had previously been treated with Trastuzumab and Taxanes. As of data cutoff date ...